Key statistics
On Monday, Immix Biopharma Inc (IMMX:NAQ) closed at 1.45, 15.08% above the 52 week low of 1.26 set on Oct 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.67 |
---|---|
High | 1.80 |
Low | 1.41 |
Bid | 1.44 |
Offer | 1.52 |
Previous close | 1.63 |
Average volume | 183.24k |
---|---|
Shares outstanding | 27.45m |
Free float | 16.42m |
P/E (TTM) | -- |
Market cap | 44.74m USD |
EPS (TTM) | -0.8411 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Announcements
- Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
- Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
- Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
- Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
- Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
- Immix Biopharma on Track to Dose NXC-201 Patients in United States
- Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
- Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
More ▼